

# Breast Disease-Oriented Team

---

Clinical Research Treatment Trial Flowchart  
CRC Contact: GRP - CTU Breast Coordinators ([CTUBreastCRC@hs.uci.edu](mailto:CTUBreastCRC@hs.uci.edu))  
Clinical Research Manager: Juan Miranda



ALL

UCI 24-05

Riluzole PO vs. Placebo PO  
Perceived worsening of *cognitive function*

**\*BREAST COHORT FULL\***

PI: Chan

CRC: Randy Kang

Accrual: 24/39

UCI 25-48

Riluzole PO vs. Placebo PO  
Perceived worsening of cognitive function

PI: Chan

CRC: Madeleine Phan

Accrual: 0/20



HER2+

HER2-

**SWOG S2206 (HER2-/low/equivocal)**

Arm 1: SOC AC-T

Arm 2: SOC AC-T + Durvalumab (IgG1k mAb)

MammaPrint Index Score MP2 required

PI: Parajuli

CRC: Madeleine Phan

Accrual: 4/10

**UCI 25-48**

Riluzole PO vs. Placebo PO

Perceived worsening of cognitive function

PI: Chan

CRC: Madeleine Phan

Accrual: 0/20



## HR+

### UCI 25-106

BMS-986517 Monotherapy  
HR+/Her2- and TNBC

PI: Dr. Nabar  
Coord: N. Arechiga/TBD  
Accrual: 0/5

## ER+

### A012301 (LoTam)

Low Dose Tamoxifen Vs SOC endocrine  
therapy for Low risk (defined in notes)

PI: Parajuli  
CRC: Juan Miranda  
Accrual: 15/30

### NRG BR007

Arm 1: RT + ET  
Arm 2: ET  
Oncotype-DX Recurrence Score  $\leq$   
18 (unless T1a tumor) required

PI: Mehta  
CRC: Stephany Ruiz  
Accrual: 3/5

### UCI 23-192 (WIDER)

Ribociclib 400mg + SOC ET +  
Goserelin or Leuprolide  
Exploratory cohort is same  
treatment

PI: Parajuli  
CRC: Stephany Ruiz  
Accrual: 2/5

### UCI 24-116 (ELEGANT)

Arm A: Elacestrant PO (SERD)  
Arm B: Physician's choice endocrine  
Tx

PI: Parajuli  
CRC: Juan Miranda  
Accrual: 0/5



■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

## HER2+

### A012303 (Any HR)

Arm 1: Trastuzumab +/- Pertuzumab every 3wks for 12months

Arm 2: Trastuzumab +/- Pertuzumab every 3wks for 12months

PI: Lavasani  
CRC: Randy Kang  
Accrual: 0/5

## TNBC

### UCI 25-106

BMS-986517 Monotherapy  
HR+/Her2- and TNBC

PI: Dr. Nabar  
Coord: N. Arechiga/TBD  
Accrual: 0/5



2L+

**UCI 19-145 (HR+/HER2-)**

CDK 4/6 inhibitor+ER Regulator+Aromatase Inhibitor

CRCs: Stephany Ruiz, Michael Rodriguez, Madeleine Phan  
Accrual: 21/40

2L+

**UCI 22-09 (TNBC, HR+/HER2-)**

XMT-1660 (ADC) – BC, EC, OC, ACC-I

Dose Esc, Backfill Cohort, Exp

**SLOT RSVP REQ (HR+/TNBC COHORT TEMP CLOSED)**

PI: Parajuli  
CRC: Juan Miranda  
Accrual: 7/10

2L+

**UCI 24-49 (HER2+ IHC 2-3+,  
HER2 Amp ISH)**

**SLOT RSVP REQ (Dose Esc)**

Dose Esc (Ph Ib):

Cohort A: Zongertinib (BI  
1810631; HER2 inhibitor) + T-  
DM1

Cohort B: BI 1810631 + T-DXd

Cohort K:

Zongertinib+Trastuzumab

PI: Dayyani  
CRC: Randy Kang  
Accrual: 3/10

**UCI 23-109 (HER2 IHC  $\geq 1+$ )**

Cohort A: HER2-Low: Disitamab Vedotin (ADC) vs. DV +  
Tucatinib

Cohort B: HER2+: DV vs. DV + Tucatinib

**SLOT RSVP REQ (Dose Esc)**

PI: Dr. Parajuli

CRC: My Nguyen; Breast CRC TBD  
Accrual: 2/10

**UCI 25-81/UCI 25-81-03 (HER2+)**

*Locally adv or Mets HER2+ prior T-DXd relapsed in 6month  
Physician Choice then either Cohort 1 or 2*

**Cohort 1:** Evorpaccept (ALX148)+Trastuzumab+Chemo

**Cohort 2:** Trastuzumab+Chemo

PI: Parajuli  
CRC: TBD  
Accrual: 0/5



**METASTATIC: 1L+**

**UCI 22-09 (TNBC, HR+/HER2-)**

XMT-1660 (ADC) – BC, EC, OC, ACC-I

Dose Esc, Backfill Cohort, Exp

**SLOT RSVP REQ (HR+/TNBC COHORT TEMP CLOSED)**

PI: Parajuli

CRC: Juan Miranda

Accrual: 6/10

**ETCTN 10546**

ASTX727 (Cytidine deaminase (CDA) inhibitor +  
nucleoside hypomethylating agent (HMA)) + Paclitaxel +  
Pembrolizumab

*DL-2 now open for TNBC*

**SLOT RSVP REQ**

PI: Parajuli

CRC: Randy Kang

Accrual: 1/5

**UCI 24-08**

SPEDOX-6 IV

**SLOT RSVP REQ**

PI: Chow

CRC: Erin Torrison; Breast CRC TBD

Accrual: 6/67

**UCI 24-195**

PF-08046054 (an ADC) monotherapy

**Dose ESC (Part A) or Schedule Optimization (Part B):**

PD-L1 expression  $\geq 1$  TPS, CPS, or % IC

**Signal-seeking cohort:** ADC monotherapy

**Biology cohort:** ADC monotherapy

PI: Nagasaka

CRC: TBD

Accrual: 0/6

METASTATIC: 1L+



ALL

## UCI 24-197

TNG456 Monotherapy or Combined w/Abemaciclib in solid tumors with MTAP Loss

**SLOT RSVP REQ**

CRC: TBD

PI: Park  
Accrual: 0/5

## UCI 24-142

Phase 1 Dose Esc

Group A: VET3-TGI monotherapy by ITu injection

Group C: VET3-TGI monotherapy by IV infusion

Group B: VET3-TGI by ITu injection, Group D: VET3-TGI IV infusion combo with pembrolizumab

**SLOT RSVP REQ**

PI: Uchio  
CRC: TBD  
Accrual: 0/4



## ALL

### UCI 22-26

CB-03-10 (PO; AR and GR antagonist)

Part 1 (esc): adv/met solid tumor

Part 2 (exp): adv/met solid tumor or relapsed/refractory

TNBC

**SLOT RSVP REQ**

HPB/Panc CRC: Miranda Duron

Breast CRC: TBD

PI: Dayyani

Accrual: 11/12

### UCI 25-75

CRN09682 IV (an MMAE) for SST2-expressing solid tumors

CRC: TBD

PI: Dayyani

Accrual: 0/15

### NRG CC014

SOC vs SOC + RT for High-risk Asymptomatic Bone

Metastases

**SLOT RSVP REQ**

PI: Harris

CRC: Natalie Arechiga; Breast CRC TBD

Accrual: 4/10



## Other Interventional/LTFU

### UCI 25-43

Type 1 Hybrid Effectiveness of a Patient-Reported Outcomes

PI: Chan  
CRC: TBD  
Accrual: 0/5

### UCI 24-87

Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Patients with Solid Tumors

PI: Arter  
CRC: TBD  
Accrual: 0/5

### NRG CC015

E-Mindfulness for living after Breast cancer

PI: Kim  
CRC: TBD  
Accrual: 0/10

**BASIC SCIENCE****UCI 18-136**

6 slots for Cohort 1/neo-adjuvant and 13 slots for Cohort 2/adjuvant  
PI: Parajuli  
CRC: Caylee Carlton  
Accrual: 79/100

**UCI 17-05 (BRCA1 -/-, +/-)**

PI: Parajuli  
CRC: Billy Joel Sanchez  
Accrual: 49/75

**Alliance A232403**

DOT Approved  
Financial Hardship study  
PI: Lavasani  
CRC: TBD  
Accrual: 0/5

**SUPPORTIVE CARE****UCI 24-64**

High fiber diet as therapy response and reduce recurrence  
  
PI: Whiteson  
CRC: TBD  
Accrual: 0/60

**UCI 25-83**

Mobile Health Intervention to Improve Adherence to Oral Anticancer Therapy  
PI: Sadigh  
CRC: TBD  
Accrual: 8/30

**UCI 25-115**

Couples Intervention for Young Adult Cancer Survivors: A Pilot Study  
PI: Hoyt  
CRC: TBD  
Accrual: 0/5



## HEALTH SERVICES RESEARCH

### UCI 25-25

PI: Eakin  
CRC: TBD  
Accrual: 0/150